In conclusion, PREDICT is a validated prognostication and treatment benefit tool that can effectively aid decision-making for adjuvant chemotherapy and trastuzumab in HER2-positive early-stage breast cancer, and in turn potentially reduce the over- and undertreatment of the disease. The gene discussed is ERBB2; the disease is breast carcinoma.